论文部分内容阅读
目的:分析并探讨宫颈小细胞癌的临床特征、治疗方法和预后因素。方法:回顾性分析2007年7月1日至2014年6月30日新疆医科大学附属肿瘤医院收治的21例宫颈小细胞癌患者的临床资料,探究宫颈小细胞癌的临床特点及预后因素。结果:按2009年国际妇产科联盟分期,ⅠB~ⅡB期16例,ⅢB~Ⅳ期5例,到随访截止日期共有4例失访,其余17例中7例发生远处转移,转移部位为肝、肺、脑、骨骼,2例局部复发;5例死亡病例生存时间分别为4、8、11、12、24个月,仅8例无瘤生存。17例患者中无瘤生存时间(PFS)为3~87个月,中位PFS为27个月,总生存时间(OS)为4~95个月,中位OS为27个月。结论:宫颈小细胞癌是一种罕见的妇科恶性肿瘤,铂类化疗是宫颈小细胞癌的一种行之有效的治疗方式,推断脉管浸润、盆腔淋巴结转移可能是宫颈小细胞癌的不良预后因素。
Objective: To analyze and discuss the clinical characteristics, treatment and prognostic factors of small cell carcinoma of the cervix. Methods: The clinical data of 21 patients with small cell carcinoma of the cervix admitted to Cancer Hospital Affiliated to Xinjiang Medical University from July 1, 2007 to June 30, 2014 were retrospectively analyzed to explore the clinical features and prognostic factors of small cell carcinoma of the cervix. Results: According to the International Federation of Obstetrics and Gynecology in 2009, 16 cases were in stage IB-IIB and 5 cases were in stage IIB-IV. Four cases were lost to the deadline of follow-up, and 7 cases were distantly metastasized in the remaining 17 cases Liver, lung, brain, bone, 2 cases of local recurrence; 5 cases of death were 4,8,11,12,24 months, only 8 cases of tumor-free survival. Seventeen patients had a PFS of 3-87 months, a median PFS of 27 months, a median overall survival (OS) of 4-95 months and a median OS of 27 months. Conclusion: Small cell carcinoma of the cervix is a rare malignant tumor of gynecology. Platinum chemotherapy is an effective treatment for small cell carcinoma of the cervix. It is concluded that vascular invasion and pelvic lymph node metastasis may be the poor prognosis of small cell carcinoma of the cervix factor.